APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioids Agonist Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Opioids Agonist Drugs Market Analysis and Forecast 2026-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchOpioids Agonist Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioids Agonist Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Opioids Agonist Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioids Agonist Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioids Agonist Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Opioids Agonist Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Opioids Agonist Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Opioids Agonist Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Opioids Agonist Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Opioids Agonist Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Opioids Agonist Drugs include Janssen Pharmaceuticals, Inc, Sun Pharmaceuticals, Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc, AbbVie Inc., Titan pharmaceuticals, Purdue Pharma and Mallinckrodt Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Opioids Agonist Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Opioids Agonist Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Opioids Agonist Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Opioids Agonist Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Opioids Agonist Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Opioids Agonist Drugs revenue, projected growth trends, production technology, application and end-user industry.

Opioids Agonist Drugs Segment by Company

Janssen Pharmaceuticals, Inc

Sun Pharmaceuticals

Sanofi

Johnson & Johnson Services, Inc.

Pfizer Inc

AbbVie Inc.

Titan pharmaceuticals

Purdue Pharma

Mallinckrodt Pharmaceuticals

Hikma Pharmaceuticals PLC

Grünenthal

Endo Pharmaceuticals Inc.

Egalet Corporation

Boehringer Ingelheim

Allergan, Plc

Opioids Agonist Drugs Segment by Type

Fentanyl

Codeine

Morphine

Methadone

Meperidine

Hydrocodone

Opioids Agonist Drugs Segment by Application

Pain Management

Cough Treatment

Diarrhea Treatment

Opioids Agonist Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioids Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioids Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioids Agonist Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Opioids Agonist Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Opioids Agonist Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Opioids Agonist Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Opioids Agonist Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Fentanyl Major Player Table 3. Codeine Major Player Table 4. Morphine Major Player Table 5. Methadone Major Player Table 6. Meperidine Major Player Table 7. Hydrocodone Major Player Table 8. Global Opioids Agonist Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Pain Management Major Player Table 10. Cough Treatment Major Player Table 11. Diarrhea Treatment Major Player Table 12. Opioids Agonist Drugs Industry Trends Table 13. Opioids Agonist Drugs Industry Drivers Table 14. Opioids Agonist Drugs Industry Opportunities and Challenges Table 15. Opioids Agonist Drugs Industry Restraints Table 16. Global Opioids Agonist Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Opioids Agonist Drugs Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Opioids Agonist Drugs Market Share by Region (2021-2026) Table 19. Global Opioids Agonist Drugs Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Opioids Agonist Drugs Market Share by Region (2027-2032) Table 21. Global Opioids Agonist Drugs Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Opioids Agonist Drugs Revenue Market Share by Players (2021-2026) Table 23. Global Opioids Agonist Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Opioids Agonist Drugs Key Players Headquarters & Area Served Table 25. Global Opioids Agonist Drugs Players, Product Type & Application Table 26. Global Opioids Agonist Drugs Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Opioids Agonist Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Opioids Agonist Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Opioids Agonist Drugs Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Opioids Agonist Drugs Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Opioids Agonist Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Opioids Agonist Drugs Revenue Market Share by Type (2027-2032) Table 34. Global Opioids Agonist Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Opioids Agonist Drugs Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Opioids Agonist Drugs Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Opioids Agonist Drugs Revenue Market Share by Application (2021-2026) Table 38. Global Opioids Agonist Drugs Revenue Market Share by Application (2027-2032) Table 39. Janssen Pharmaceuticals, Inc Company Information Table 40. Janssen Pharmaceuticals, Inc Business Overview Table 41. Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Product Portfolio Table 43. Janssen Pharmaceuticals, Inc Recent Development Table 44. Sun Pharmaceuticals Company Information Table 45. Sun Pharmaceuticals Business Overview Table 46. Sun Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Sun Pharmaceuticals Opioids Agonist Drugs Product Portfolio Table 48. Sun Pharmaceuticals Recent Development Table 49. Sanofi Company Information Table 50. Sanofi Business Overview Table 51. Sanofi Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Sanofi Opioids Agonist Drugs Product Portfolio Table 53. Sanofi Recent Development Table 54. Johnson & Johnson Services, Inc. Company Information Table 55. Johnson & Johnson Services, Inc. Business Overview Table 56. Johnson & Johnson Services, Inc. Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Johnson & Johnson Services, Inc. Opioids Agonist Drugs Product Portfolio Table 58. Johnson & Johnson Services, Inc. Recent Development Table 59. Pfizer Inc Company Information Table 60. Pfizer Inc Business Overview Table 61. Pfizer Inc Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Pfizer Inc Opioids Agonist Drugs Product Portfolio Table 63. Pfizer Inc Recent Development Table 64. AbbVie Inc. Company Information Table 65. AbbVie Inc. Business Overview Table 66. AbbVie Inc. Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. AbbVie Inc. Opioids Agonist Drugs Product Portfolio Table 68. AbbVie Inc. Recent Development Table 69. Titan pharmaceuticals Company Information Table 70. Titan pharmaceuticals Business Overview Table 71. Titan pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Titan pharmaceuticals Opioids Agonist Drugs Product Portfolio Table 73. Titan pharmaceuticals Recent Development Table 74. Purdue Pharma Company Information Table 75. Purdue Pharma Business Overview Table 76. Purdue Pharma Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Purdue Pharma Opioids Agonist Drugs Product Portfolio Table 78. Purdue Pharma Recent Development Table 79. Mallinckrodt Pharmaceuticals Company Information Table 80. Mallinckrodt Pharmaceuticals Business Overview Table 81. Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Product Portfolio Table 83. Mallinckrodt Pharmaceuticals Recent Development Table 84. Hikma Pharmaceuticals PLC Company Information Table 85. Hikma Pharmaceuticals PLC Business Overview Table 86. Hikma Pharmaceuticals PLC Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Hikma Pharmaceuticals PLC Opioids Agonist Drugs Product Portfolio Table 88. Hikma Pharmaceuticals PLC Recent Development Table 89. Grünenthal Company Information Table 90. Grünenthal Business Overview Table 91. Grünenthal Opioids Agonist Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Grünenthal Opioids Agonist Drugs Product Portfolio Table 93. Grünenthal Recent Development Table 94. Endo Pharmaceuticals Inc. Company Information Table 95. Endo Pharmaceuticals Inc. Business Overview Table 96. Endo Pharmaceuticals Inc. Opioids Agonist Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Endo Pharmaceuticals Inc. Opioids Agonist Drugs Product Portfolio Table 98. Endo Pharmaceuticals Inc. Recent Development Table 99. Egalet Corporation Company Information Table 100. Egalet Corporation Business Overview Table 101. Egalet Corporation Opioids Agonist Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Egalet Corporation Opioids Agonist Drugs Product Portfolio Table 103. Egalet Corporation Recent Development Table 104. Boehringer Ingelheim Company Information Table 105. Boehringer Ingelheim Business Overview Table 106. Boehringer Ingelheim Opioids Agonist Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Boehringer Ingelheim Opioids Agonist Drugs Product Portfolio Table 108. Boehringer Ingelheim Recent Development Table 109. Allergan, Plc Company Information Table 110. Allergan, Plc Business Overview Table 111. Allergan, Plc Opioids Agonist Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Allergan, Plc Opioids Agonist Drugs Product Portfolio Table 113. Allergan, Plc Recent Development Table 114. North America Opioids Agonist Drugs Revenue by Type (2021-2026) & (US$ Million) Table 115. North America Opioids Agonist Drugs Revenue by Type (2027-2032) & (US$ Million) Table 116. North America Opioids Agonist Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. North America Opioids Agonist Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. North America Opioids Agonist Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Opioids Agonist Drugs Revenue by Country (2021-2026) & (US$ Million) Table 120. North America Opioids Agonist Drugs Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe Opioids Agonist Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Opioids Agonist Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Opioids Agonist Drugs Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe Opioids Agonist Drugs Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe Opioids Agonist Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe Opioids Agonist Drugs Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe Opioids Agonist Drugs Revenue by Country (US$ Million) & (2027-2032) Table 128. China Opioids Agonist Drugs Revenue by Type (2021-2026) & (US$ Million) Table 129. China Opioids Agonist Drugs Revenue by Type (2027-2032) & (US$ Million) Table 130. China Opioids Agonist Drugs Revenue by Application (2021-2026) & (US$ Million) Table 131. China Opioids Agonist Drugs Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Opioids Agonist Drugs Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia Opioids Agonist Drugs Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia Opioids Agonist Drugs Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia Opioids Agonist Drugs Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia Opioids Agonist Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia Opioids Agonist Drugs Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia Opioids Agonist Drugs Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA Opioids Agonist Drugs Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA Opioids Agonist Drugs Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA Opioids Agonist Drugs Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA Opioids Agonist Drugs Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA Opioids Agonist Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA Opioids Agonist Drugs Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA Opioids Agonist Drugs Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Opioids Agonist Drugs Image Figure 2. Global Opioids Agonist Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioids Agonist Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Fentanyl Image Figure 5. Codeine Image Figure 6. Morphine Image Figure 7. Methadone Image Figure 8. Meperidine Image Figure 9. Hydrocodone Image Figure 10. Global Opioids Agonist Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Opioids Agonist Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 12. Pain Management Image Figure 13. Cough Treatment Image Figure 14. Diarrhea Treatment Image Figure 15. Global Opioids Agonist Drugs Market Size (US$ Million) & (2021-2032) Figure 16. Global Opioids Agonist Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Opioids Agonist Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Opioids Agonist Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Opioids Agonist Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Opioids Agonist Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Opioids Agonist Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global Opioids Agonist Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Opioids Agonist Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Opioids Agonist Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Opioids Agonist Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Opioids Agonist Drugs Revenue Share by Type (2021-2032) Figure 28. North America Opioids Agonist Drugs Revenue Share by Application (2021-2032) Figure 29. North America Opioids Agonist Drugs Revenue Share by Country (2021-2032) Figure 30. United States Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Opioids Agonist Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Opioids Agonist Drugs Revenue Share by Type (2021-2032) Figure 35. Europe Opioids Agonist Drugs Revenue Share by Application (2021-2032) Figure 36. Europe Opioids Agonist Drugs Revenue Share by Country (2021-2032) Figure 37. Germany Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Opioids Agonist Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Opioids Agonist Drugs Revenue Share by Type (2021-2032) Figure 47. China Opioids Agonist Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Opioids Agonist Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Opioids Agonist Drugs Revenue Share by Type (2021-2032) Figure 50. Asia Opioids Agonist Drugs Revenue Share by Application (2021-2032) Figure 51. Asia Opioids Agonist Drugs Revenue Share by Region (2021-2032) Figure 52. Japan Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Opioids Agonist Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Opioids Agonist Drugs Revenue Share by Type (2021-2032) Figure 60. SAMEA Opioids Agonist Drugs Revenue Share by Application (2021-2032) Figure 61. SAMEA Opioids Agonist Drugs Revenue Share by Country (2021-2032) Figure 62. Brazil Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Opioids Agonist Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Fentanyl
  • Codeine
  • Morphine
  • Methadone
  • Meperidine
  • Hydrocodone
Applications
  • Pain Management
  • Cough Treatment
  • Diarrhea Treatment
Companies covered
  • Janssen Pharmaceuticals, Inc
  • Sun Pharmaceuticals
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc
  • AbbVie Inc.
  • Titan pharmaceuticals
  • Purdue Pharma
  • Mallinckrodt Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Grünenthal
  • Endo Pharmaceuticals Inc.
  • Egalet Corporation
  • Boehringer Ingelheim
  • Allergan, Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Opioids Agonist Drugs Market by Type
  3. 1.2.1 Global Opioids Agonist Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Fentanyl
  5. 1.2.3 Codeine
  6. 1.2.4 Morphine
  7. 1.2.5 Methadone
  8. 1.2.6 Meperidine
  9. 1.2.7 Hydrocodone
  10. 1.3 Opioids Agonist Drugs Market by Application
  11. 1.3.1 Global Opioids Agonist Drugs Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Pain Management
  13. 1.3.3 Cough Treatment
  14. 1.3.4 Diarrhea Treatment
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Opioids Agonist Drugs Market Dynamics
  1. 2.1 Opioids Agonist Drugs Industry Trends
  2. 2.2 Opioids Agonist Drugs Industry Drivers
  3. 2.3 Opioids Agonist Drugs Industry Opportunities and Challenges
  4. 2.4 Opioids Agonist Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Opioids Agonist Drugs Market Perspective (2021-2032)
  2. 3.2 Global Opioids Agonist Drugs Growth Trends by Region
  3. 3.2.1 Global Opioids Agonist Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Opioids Agonist Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Opioids Agonist Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Opioids Agonist Drugs Revenue by Players
  2. 4.1.1 Global Opioids Agonist Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Opioids Agonist Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Opioids Agonist Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Opioids Agonist Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Opioids Agonist Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Opioids Agonist Drugs Players, Product Type & Application
  8. 4.5 Global Opioids Agonist Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Opioids Agonist Drugs Market CR5 and HHI
  11. 4.6.3 2025 Opioids Agonist Drugs Tier 1, Tier 2, and Tier 3
5 Opioids Agonist Drugs Market Size by Type
  1. 5.1 Global Opioids Agonist Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Opioids Agonist Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Opioids Agonist Drugs Revenue Market Share by Type (2021-2032)
6 Opioids Agonist Drugs Market Size by Application
  1. 6.1 Global Opioids Agonist Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Opioids Agonist Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Opioids Agonist Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Janssen Pharmaceuticals, Inc
  2. 7.1.1 Janssen Pharmaceuticals, Inc Company Information
  3. 7.1.2 Janssen Pharmaceuticals, Inc Business Overview
  4. 7.1.3 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Product Portfolio
  6. 7.1.5 Janssen Pharmaceuticals, Inc Recent Developments
  7. 7.2 Sun Pharmaceuticals
  8. 7.2.1 Sun Pharmaceuticals Company Information
  9. 7.2.2 Sun Pharmaceuticals Business Overview
  10. 7.2.3 Sun Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sun Pharmaceuticals Opioids Agonist Drugs Product Portfolio
  12. 7.2.5 Sun Pharmaceuticals Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Opioids Agonist Drugs Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Johnson & Johnson Services, Inc.
  20. 7.4.1 Johnson & Johnson Services, Inc. Company Information
  21. 7.4.2 Johnson & Johnson Services, Inc. Business Overview
  22. 7.4.3 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Product Portfolio
  24. 7.4.5 Johnson & Johnson Services, Inc. Recent Developments
  25. 7.5 Pfizer Inc
  26. 7.5.1 Pfizer Inc Company Information
  27. 7.5.2 Pfizer Inc Business Overview
  28. 7.5.3 Pfizer Inc Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Inc Opioids Agonist Drugs Product Portfolio
  30. 7.5.5 Pfizer Inc Recent Developments
  31. 7.6 AbbVie Inc.
  32. 7.6.1 AbbVie Inc. Company Information
  33. 7.6.2 AbbVie Inc. Business Overview
  34. 7.6.3 AbbVie Inc. Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Inc. Opioids Agonist Drugs Product Portfolio
  36. 7.6.5 AbbVie Inc. Recent Developments
  37. 7.7 Titan pharmaceuticals
  38. 7.7.1 Titan pharmaceuticals Company Information
  39. 7.7.2 Titan pharmaceuticals Business Overview
  40. 7.7.3 Titan pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Titan pharmaceuticals Opioids Agonist Drugs Product Portfolio
  42. 7.7.5 Titan pharmaceuticals Recent Developments
  43. 7.8 Purdue Pharma
  44. 7.8.1 Purdue Pharma Company Information
  45. 7.8.2 Purdue Pharma Business Overview
  46. 7.8.3 Purdue Pharma Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Purdue Pharma Opioids Agonist Drugs Product Portfolio
  48. 7.8.5 Purdue Pharma Recent Developments
  49. 7.9 Mallinckrodt Pharmaceuticals
  50. 7.9.1 Mallinckrodt Pharmaceuticals Company Information
  51. 7.9.2 Mallinckrodt Pharmaceuticals Business Overview
  52. 7.9.3 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Product Portfolio
  54. 7.9.5 Mallinckrodt Pharmaceuticals Recent Developments
  55. 7.10 Hikma Pharmaceuticals PLC
  56. 7.10.1 Hikma Pharmaceuticals PLC Company Information
  57. 7.10.2 Hikma Pharmaceuticals PLC Business Overview
  58. 7.10.3 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Product Portfolio
  60. 7.10.5 Hikma Pharmaceuticals PLC Recent Developments
  61. 7.11 Grünenthal
  62. 7.11.1 Grünenthal Company Information
  63. 7.11.2 Grünenthal Business Overview
  64. 7.11.3 Grünenthal Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Grünenthal Opioids Agonist Drugs Product Portfolio
  66. 7.11.5 Grünenthal Recent Developments
  67. 7.12 Endo Pharmaceuticals Inc.
  68. 7.12.1 Endo Pharmaceuticals Inc. Company Information
  69. 7.12.2 Endo Pharmaceuticals Inc. Business Overview
  70. 7.12.3 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Product Portfolio
  72. 7.12.5 Endo Pharmaceuticals Inc. Recent Developments
  73. 7.13 Egalet Corporation
  74. 7.13.1 Egalet Corporation Company Information
  75. 7.13.2 Egalet Corporation Business Overview
  76. 7.13.3 Egalet Corporation Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Egalet Corporation Opioids Agonist Drugs Product Portfolio
  78. 7.13.5 Egalet Corporation Recent Developments
  79. 7.14 Boehringer Ingelheim
  80. 7.14.1 Boehringer Ingelheim Company Information
  81. 7.14.2 Boehringer Ingelheim Business Overview
  82. 7.14.3 Boehringer Ingelheim Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Boehringer Ingelheim Opioids Agonist Drugs Product Portfolio
  84. 7.14.5 Boehringer Ingelheim Recent Developments
  85. 7.15 Allergan, Plc
  86. 7.15.1 Allergan, Plc Company Information
  87. 7.15.2 Allergan, Plc Business Overview
  88. 7.15.3 Allergan, Plc Opioids Agonist Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Allergan, Plc Opioids Agonist Drugs Product Portfolio
  90. 7.15.5 Allergan, Plc Recent Developments
8 North America
  1. 8.1 North America Opioids Agonist Drugs Revenue (2021-2032)
  2. 8.2 North America Opioids Agonist Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Opioids Agonist Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Opioids Agonist Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Opioids Agonist Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Opioids Agonist Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Opioids Agonist Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Opioids Agonist Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Opioids Agonist Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Opioids Agonist Drugs Revenue by Country
  11. 8.6.1 North America Opioids Agonist Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Opioids Agonist Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Opioids Agonist Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Opioids Agonist Drugs Revenue (2021-2032)
  2. 9.2 Europe Opioids Agonist Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Opioids Agonist Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Opioids Agonist Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Opioids Agonist Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Opioids Agonist Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Opioids Agonist Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Opioids Agonist Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Opioids Agonist Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Opioids Agonist Drugs Revenue by Country
  11. 9.6.1 Europe Opioids Agonist Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Opioids Agonist Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Opioids Agonist Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Opioids Agonist Drugs Revenue (2021-2032)
  2. 10.2 China Opioids Agonist Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Opioids Agonist Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Opioids Agonist Drugs Revenue by Type (2027-2032)
  5. 10.3 China Opioids Agonist Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Opioids Agonist Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Opioids Agonist Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Opioids Agonist Drugs Revenue by Application (2027-2032)
  9. 10.5 China Opioids Agonist Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Opioids Agonist Drugs Revenue (2021-2032)
  2. 11.2 Asia Opioids Agonist Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Opioids Agonist Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Opioids Agonist Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Opioids Agonist Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Opioids Agonist Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Opioids Agonist Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Opioids Agonist Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Opioids Agonist Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Opioids Agonist Drugs Revenue by Country
  11. 11.6.1 Asia Opioids Agonist Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Opioids Agonist Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Opioids Agonist Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Opioids Agonist Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Opioids Agonist Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Opioids Agonist Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Opioids Agonist Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Opioids Agonist Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Opioids Agonist Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Opioids Agonist Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Opioids Agonist Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Opioids Agonist Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Opioids Agonist Drugs Revenue by Country
  11. 12.6.1 SAMEA Opioids Agonist Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Opioids Agonist Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Opioids Agonist Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst